Finally, even if sufficiently high systemic levels of SCFAs are reached, it will be essential to prevent comorbidity-related adverse effects such as hyperphagia, hypertriglyceridemia, ectopic lipid deposition in liver and skeletal muscle, and liver and muscle insulin resistance (96). Here, INS is linked to hypertriglyceridemia.